Buy GANX by Sep 27, 2026.

Good News here: # Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease BETHESDA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application for GT-02287. The FDA's …